Novel Electronic Monitoring Devices (NEMD) to Monitor Adherence in Children With Asthma (NEMD)
Primary Purpose
Asthma in Children
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Novel Electronic Monitoring Device
Sponsored by
About this trial
This is an interventional device feasibility trial for Asthma in Children focused on measuring Asthma, Children, Adherence, Electronic Monitoring devices (EMD), Inhalers, Inhaled medication
Eligibility Criteria
Inclusion Criteria:
- Informed consent obtained from parents/guardian/adolescents and/or assent from the child.
- Children aged between 6-16 years with a diagnosis of asthma attending the Royal Brompton and Harefield Difficult asthma clinic.
- Children on inhaled cortico-steroids
- Parents/ young person has a mobile phone which can download apps
- Paediatric respiratory nurses working in the difficult asthma team at Royal Brompton Hospital.
Exclusion Criteria:
- Unable to provide consent
- As a result of medical interview, physical examination or screening investigation the physician responsible considers the child unfit for the study.
- Those who, in the opinion of the investigator, have a risk of non-compliance with study procedures
- Children under the age of 6 years.
- Children not on inhaled cortico-steroid
- It is not anticipated that any children will be pregnant, however, if they are they will not be included in the study
Sites / Locations
- Royal Brompton Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
R-DOT
Haillie
Rafi-tone/INCA
Arm Description
Remote Directly Observed Therapy
Smartinhaler Haillie
Rafi-tone with Flo-tone /INCA
Outcomes
Primary Outcome Measures
Acceptability Using Semi Structured Questionnaires in Focus Groups and Interviews
Number of participant interviewed in focus groups and interviews
Number of Themes Generated by Participants Regarding Usage of the Devices
The Primary outcome measure is largely qualitative and based on collective themes. As a result there are no numerical measurements that differ each of the devices. In terms of accuracy of each device adherence data was collected but differs for each device depending on its functionality
Secondary Outcome Measures
Adherence to Inhaled Medication
Percentage adherence to inhaled corticosteroids
Full Information
NCT ID
NCT04289714
First Posted
February 21, 2020
Last Updated
October 5, 2020
Sponsor
Imperial College London
Collaborators
Asthma UK
1. Study Identification
Unique Protocol Identification Number
NCT04289714
Brief Title
Novel Electronic Monitoring Devices (NEMD) to Monitor Adherence in Children With Asthma
Acronym
NEMD
Official Title
A Feasibility Study to Assess Novel Electronic Monitoring Devices (NEMD) for Monitoring Adherence in Children With Asthma
Study Type
Interventional
2. Study Status
Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
October 12, 2018 (Actual)
Primary Completion Date
May 18, 2019 (Actual)
Study Completion Date
May 18, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imperial College London
Collaborators
Asthma UK
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a feasibility study to assess novel electronic monitoring devices for monitoring adherence in children with asthma who are on inhaled corticosteroids (ICS)
It is a mixed method (quantitative and qualitative) open label, pragmatic randomised feasibility study with two main aims:
To assess the feasibility of 4 novel electronic monitoring devices in children aged 6-16 years with asthma, in terms of usability and acceptability by patients/ guardians and healthcare professionals (qualitative study)
To evaluate the accuracy of these devices and assess whether they impact on asthma control (quantitative study).
The duration of study is 16 weeks.
Detailed Description
This was an open label, block randomised (10 in each block), mixed method (quantitative and qualitative) study to be conducted for a period of up to 16 weeks
Children aged between 6-16 years with asthma attending the paediatric respiratory difficult asthma clinic will be recruited into the study and randomly allocated to one of three arms using block randomisation matched for age and size of group. Children will be assigned to trial one of the following four NEMD's to be tested:
Block 1 (10): Smart-inhaler Plus™ (Adherium, New Zealand)
• This measures inhalation usually flow sensors and is the next generation of a currently commercially available EMD
Block 2a (5) : Flo-Tone (Clement Clarke, UK) plus Rafi-tone, acoustic enabled Smartphone App (clin-e-cal, UK) for children aged 6 - 11 years • The Flo-Tone attaches to a Metered Dose Inhaler (MDI) and makes a sound when the inhaler is used correctly. Rafi-tone is a Smartphone App that detects the sound and activates a game The game is aimed at younger children and therefore children aged 6 - 11 years will be randomised to this block.
Block 2b (5) : Inhaler Compliance Assessment (INCA™) device (INCA, Ireland)
This is an audio recording device which attaches to a Discus dry powder inhaler. Analysis of the digital audio recordings enables objective assessment of inhaler use and technique. As it can only be used with a Discus only children ≥ 12 years will be randomised to this block
3. Block 3: Video and Remote Directly Observed treatment (rDOT)
Children are filmed on a Smartphone using their inhaler. The clip is then automatically uploaded via a Smartphone App (Continga, UK) and reviewed by a Clinical Nurse Specialist to ensure inhaler technique is correct.
Recruitment :
The aim was to recruit 30 children into the study; 10 per block, and 5 per block aged 6-11 years and 5 aged 12-16 years for the INCA/Rafi-tone arm. However, due to low number of participants completing the study, ethics approval was sought to extend the study. As a result 35 participants were recruited at the end of the study period.
Visit 1:Novel electronic monitoring device (NEMD) issued Routine clinical care assessments will be carried out at the end of the study period as below, including asthma control test (ACT) or the childhood asthma control test (cACT), exhaled nitric oxide (FeNO) and spirometry (FEV1 and BDR) .
Patient/parent/Carer will be invited to take part in the study. Information regarding the study and its objectives will be communicated to the Patient/parent/carer in both oral and written form using patient information leaflets.
All children will be issued with a novel electronic monitoring device which will be attached to the child's usual inhaler or require an app on their mobile phone as described above. Parents and children will be provided information and advice on the use of the novel electronic monitoring device and asked to conduct up to 16 weeks of home monitoring using their allocated NEMD on their first visit.
Information on how to contact the team in case of any problems will be related to the participant in both oral and written form.
The data will be stored electronically and downloaded at the next clinic visit. Contact by telephone will be made at day 7-14 to ensure that the device is working and to answer any other queries then at week 6-7 to determine if the device is being used appropriately and to answer any related questions.
Week 1 - for the rDOT arm, adherence data will be downloaded to check for consistencies in inhaler technique. If inhaler technique is inaccurate, the participants will be called by the respiratory nurse specialists to advise on correct technique. This will be documented as part of the data collection.
Week 4 - All devices, adherence data will be downloaded and checked to ensure that the devices are working correctly.
Visit 2: up to 12 weeks of adherence data collection Routine clinical care assessments will be carried out at the end of the study period as below, including asthma control test (ACT) or the childhood asthma control test (cACT), exhaled nitric oxide and spirometry (FEV1 and BDR) .
Adherence data will downloaded at the end of the study period and stored electronically.
Visit 3: Focus group or one to one interviews The participants and their carers will be invited to a face to face focus group interview, or a one to one interview, depending on their availability at the end of the study period. The focus group and one to one interviews will utilise a semi structured questionnaire, to provide qualitative feedback on the acceptability and usability of the devices.
A separate focus group meeting will also be conducted with the paediatric respiratory nurses who are part of the Multi disciplinary Team (MDT) to assess their views on the devices used as they routinely provided all asthma devices and are also involved in downloading data from other devices that the investigators would use as part of routine care (smart-inhaler). They will also be consented to take part in the study Where possible a second researcher from University College London (UCL), Christina Pearce will sit in the focus groups discussion and interviews to ensure there is no bias.
The conversations from the focus group and one to one interviews will be transcribed and coded into themes. The investigators will utilise an external company for transcribing the conversations called 1st Class.
Analysis
Qualitative:
The focus group and one to one interviews will be audio recorded, transcribed and put into themes to conduct an inductive thematic analysis. 25% of the transcripts (8) will be double coded by an independent researcher from UCL, Dr Amy Chan, experienced in qualitative research to ensure that the correct themes have been used and to ensure that there is no bias.
The focus group and one to one interviews will be used to assess the usability and acceptability of the devices
Quantitative:
The amount of usable data from each device will be quantified and compared. This will provide data on the perceived accuracy of the device.
The quantitative and qualitative results will be amalgamated and an evidence report prepared to assess the feasibility of each device.
An expert panel will be convened to select the most appropriate device to take forward to a larger randomised controlled trial to assess the impact of the device on adherence in children with asthma.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma in Children
Keywords
Asthma, Children, Adherence, Electronic Monitoring devices (EMD), Inhalers, Inhaled medication
7. Study Design
Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Feasibility Pragmatic randomisation
Masking
None (Open Label)
Masking Description
Pragmatic randomization based on inhaled medication
Allocation
Non-Randomized
Enrollment
35 (Actual)
8. Arms, Groups, and Interventions
Arm Title
R-DOT
Arm Type
Experimental
Arm Description
Remote Directly Observed Therapy
Arm Title
Haillie
Arm Type
Experimental
Arm Description
Smartinhaler Haillie
Arm Title
Rafi-tone/INCA
Arm Type
Experimental
Arm Description
Rafi-tone with Flo-tone /INCA
Intervention Type
Device
Intervention Name(s)
Novel Electronic Monitoring Device
Intervention Description
Four Novel electronic Monitoring Devices were trialled
Primary Outcome Measure Information:
Title
Acceptability Using Semi Structured Questionnaires in Focus Groups and Interviews
Description
Number of participant interviewed in focus groups and interviews
Time Frame
16 weeks
Title
Number of Themes Generated by Participants Regarding Usage of the Devices
Description
The Primary outcome measure is largely qualitative and based on collective themes. As a result there are no numerical measurements that differ each of the devices. In terms of accuracy of each device adherence data was collected but differs for each device depending on its functionality
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
Adherence to Inhaled Medication
Description
Percentage adherence to inhaled corticosteroids
Time Frame
16 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Informed consent obtained from parents/guardian/adolescents and/or assent from the child.
Children aged between 6-16 years with a diagnosis of asthma attending the Royal Brompton and Harefield Difficult asthma clinic.
Children on inhaled cortico-steroids
Parents/ young person has a mobile phone which can download apps
Paediatric respiratory nurses working in the difficult asthma team at Royal Brompton Hospital.
Exclusion Criteria:
Unable to provide consent
As a result of medical interview, physical examination or screening investigation the physician responsible considers the child unfit for the study.
Those who, in the opinion of the investigator, have a risk of non-compliance with study procedures
Children under the age of 6 years.
Children not on inhaled cortico-steroid
It is not anticipated that any children will be pregnant, however, if they are they will not be included in the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Louise Fleming, MD
Organizational Affiliation
Imperial College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royal Brompton Hospital
City
London
ZIP/Postal Code
SW3 6NP
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Anonymous data will be shared in a publication format.
IPD Sharing Time Frame
6 months from publication
IPD Sharing Access Criteria
For publication purposes by the Principal investigator and the study team
Learn more about this trial
Novel Electronic Monitoring Devices (NEMD) to Monitor Adherence in Children With Asthma
We'll reach out to this number within 24 hrs